Lejeune A, Moorjani M, Gicquaud C, Lacroix J, Poyet P, Gaudreault R
Département de Chimie-Biologie, Université du Québec à Trois-Rivières, Canada.
Anticancer Res. 1994 May-Jun;14(3A):915-9.
Liposomes and monoclonal antibodies are used as drug carriers for the optimal delivery of pharmacologic agents. However, they present disadvantages that led us to develop a new model of drug carriers: the nanoerythrosomes. Nanoerythrosomes are vesicles prepared by the extrusion of red blood cell ghosts, the average diameter of these vesicles is 0.1 micron. Daunorubicin was covalently linked to nanoerythrosomes and the cytotoxicity of daunorubicin conjugated to nanoerythrosomes was assessed on P388D1 cell line. The results indicated that the cytotoxicity of conjugated daunorubicin was as high as the free daunorubicin. Daunorubicin--nanoerythrosome conjugates had a higher antineoplastic activity than the free drug on CDF1 leukemia tumors. These results indicate that nonoerythrosomes could be potentially used as drug carriers.
脂质体和单克隆抗体被用作药物载体，以实现药理剂的最佳递送。然而，它们存在一些缺点，这促使我们开发一种新的药物载体模型：纳米红细胞体。纳米红细胞体是通过挤压红细胞影体制备的囊泡，这些囊泡的平均直径为0.1微米。柔红霉素与纳米红细胞体共价连接，并在P388D1细胞系上评估了与纳米红细胞体结合的柔红霉素的细胞毒性。结果表明，结合的柔红霉素的细胞毒性与游离柔红霉素一样高。柔红霉素-纳米红细胞体缀合物在CDF1白血病肿瘤上比游离药物具有更高的抗肿瘤活性。这些结果表明，纳米红细胞体有可能用作药物载体。
